Fatal Cisplatin Overdose in the Treatment of Mediastinal Lymphoma with the ESHAP Regimen – Analysis of the Causes of the Adverse Drug Event

Publisher： Karger

E-ISSN： 2296-5262|36|1-2|49-52

ISSN： 2296-5270

Source： Oncology Research and Treatment, Vol.36, Iss.1-2, 2013-01, pp. : 49-52

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Phase II trial of ofatumumab plus ESHAP (O‐ESHAP) as salvage treatment for patients with relapsed or refractory classical Hodgkin lymphoma after first‐line chemotherapy

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 174, Iss. 6, 2016-09 ,pp. : 859-867

John Wiley & Sons Inc

Access to resources Recommend Favorite

Novel Data‐Mining Methodologies for Adverse Drug Event Discovery and Analysis

By  

CLINICAL PHARMACOLOGY & THERAPEUTICS, Vol. 91, Iss. 6, 2012-06 ,pp. : 1010-1021

John Wiley & Sons Inc

Access to resources Recommend Favorite

Drug-Related Mortality and Fatal Overdose Risk: Pilot Cohort Study of Heroin Users Recruited From Specialist Drug Treatment Sites in London

By Hickman Matthew   Carnwath Zenobia   Madden Peter   Farrell Michael   Rooney Cleone   Ashcroft Richard   Judd Ali   Stimson Gerry  

Journal of Urban Health: Bulletin of the New York Academy of Medicine, Vol. 80, Iss. 2, 2003-06 ,pp. : 274-287

Springer Publishing Company

Access to resources Recommend Favorite

Impact of a Swiss adverse drug event prevention collaborative

By  

JOURNAL OF EVALUATION IN CLINICAL PRACTICE (ELECTRONIC), Vol. 21, Iss. 4, 2015-08 ,pp. : 717-726

John Wiley & Sons Inc

Access to resources Recommend Favorite

Rituximab, Gemcitabine, Cisplatin and Methylprednisolone (R‐GEM‐P) is an effective regimen in relapsed diffuse large B‐cell lymphoma

By  

EUROPEAN JOURNAL OF HAEMATOLOGY, Vol. 94, Iss. 3, 2015-03 ,pp. : 219-226

John Wiley & Sons Inc

Access to resources Recommend Favorite